Financings

Creabilis SA raised $20 million in a Series B financing.

Puma Biotechnology Inc. raised $55 million in a private placement after going public in a reverse merger.

Deals

Agios Pharmaceuticals Inc. got $20 million as partner Celgene Corp. extended a cancer metabolism deal.

Alexza Pharmaceuticals Inc. licensed some ex-U.S. Adasuve (staccato loxapine) rights to Grupo Ferrer International SA.

Gilead Sciences Inc. licensed an HIV integrase inhibitor program from Boehringer Ingelheim GmbH.

Intellect Neurosciences Inc. licensed a Friedreich's ataxia drug to ViroPharma Inc. for $126.5 million.

Ono Pharmaceutical Co. Ltd. got $26.1 million up front from Merck KGaA for two clinical products.

Puma Biotechnology Inc. licensed clinical-stage kinase inhibitor neratinib from Pfizer Inc.

Unigene Laboratories Inc. and Nordic Bioscience AS formed a joint venture for calcitonin analogues.

. . . And More

Adventrx Pharmaceuticals Inc. is looking to partner Exelbine after the FDA required another trial.

Emergent BioSolutions Inc. won a $1.25 billion contract for BioThrax (anthrax vaccine adsorbed).

The Nobel Prize in physiology or medicine was awarded to Ralph Steinman for his discovery of the dendritic cell, and to Bruce Beutler and Jules Hoffmann for their discoveries regarding innate immunity.

Sangamo BioSciences Inc. dropped SB-509 after a Phase IIb failure in diabetic neuropathy.